{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-23-004890","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.288876+00:00","generated_at":"2026-06-13T02:19:37.727341+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024","bullets":["No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.","Studies include knee osteoarthritis, moderate-to-severe COVID-19, and long-haul COVID-19 (expected completion October 2023).","Company plans to initiate larger Phase 2 studies for multiple chronic conditions in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-23-004890","json":"https://secwatch.observer/filing/0001829126-23-004890.json","markdown":"https://secwatch.observer/filing/0001829126-23-004890.md","text":"https://secwatch.observer/filing/0001829126-23-004890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/0001829126-23-004890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912623004890/organicellregen_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:19:37.727341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}